Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection

QR Code

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Elvira Baos, Alberto Delgado-Iribarren, Silvia O´Connor, Ignacio Bardón, Mar Alvaréz, Iciar Rodríguez-Avial, Esther Culebras
Format:	article
Langue:	EN
Publié:	Elsevier 2022
Sujets:	Infectious and parasitic diseases RC109-216
Accès en ligne:	https://doaj.org/article/20752589e6eb44048f91a1655eda75a4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
par: Ilaria Vicenti, et autres
Publié: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
par: Esther Saiag, et autres
Publié: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
par: Krzysztof Lukaszuk, et autres
Publié: (2021)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
par: Shai Efrati, et autres
Publié: (2021)

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine
par: Mira FS, et autres
Publié: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
par: Nicola Silvestris
Publié: (2021)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
par: Julie Demaret, et autres
Publié: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
par: Timothy A. Bates, et autres
Publié: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
par: Yamato Nishiguchi, et autres
Publié: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
par: Akihiro Matsubara, et autres
Publié: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
par: Toshiyuki Sumi, et autres
Publié: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
par: Benjamin Kahn, BA, et autres
Publié: (2021)

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
par: Tariq Azamgarhi, et autres
Publié: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
par: Jia Ming Low, et autres
Publié: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
par: Jing Zou, et autres
Publié: (2021)

Percentage of Students Using Drugs During the Previous 30 Days: 1991-98
Publié: (2000)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
par: Chin-Shern Lau, et autres
Publié: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
par: Delphina Gomes, et autres
Publié: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
par: Davide Ferrari, et autres
Publié: (2021)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
par: Mohammad Shehab, et autres
Publié: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
par: Delphina Gomes, et autres
Publié: (2021)

B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
par: Federica Pulvirenti, et autres
Publié: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
par: Kazuki Takada, MD, PhD, et autres
Publié: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
par: Rana Shibli, et autres
Publié: (2021)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
par: Hamad Ali, et autres
Publié: (2021)

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
par: Serge Goldman, et autres
Publié: (2021)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
par: Michael Cross, et autres
Publié: (2021)

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
par: Rolf Schwarzer, et autres
Publié: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
par: Kenji Maeda, et autres
Publié: (2021)

Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS
par: Domenico Pascucci, et autres
Publié: (2021)

Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
par: Dafna Yahav, et autres
Publié: (2021)

Acta No. 162
par: Banco Central de Chile
Publié: (2019)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
par: Doris Urlaub, et autres
Publié: (2021)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
par: Chiara Agrati, et autres
Publié: (2021)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
par: M.D. Maldonado, et autres
Publié: (2021)

Percentage of White Students in Ethnic Schools Against Overall Percentages
Publié: (2000)

Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
par: Matteo Nioi, et autres
Publié: (2021)

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
par: Peter Bergman, MD, et autres
Publié: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
par: Shepherd R. Singer, M.D., et autres
Publié: (2021)

The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients
par: Anila Duni, et autres
Publié: (2021)